Nuveen Asset Management LLC Has $12.12 Million Position in ICU Medical, Inc. (NASDAQ:ICUI)

Nuveen Asset Management LLC cut its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 10.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,097 shares of the medical instruments supplier's stock after selling 8,867 shares during the quarter. Nuveen Asset Management LLC owned about 0.32% of ICU Medical worth $12,118,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd acquired a new position in ICU Medical in the fourth quarter worth about $33,000. Quarry LP grew its stake in ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 214 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in ICU Medical in the fourth quarter worth about $52,000. Venturi Wealth Management LLC grew its stake in ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock worth $82,000 after purchasing an additional 206 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 300 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, COO Christian B. Voigtlander sold 5,555 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $135.55, for a total transaction of $752,980.25. Following the sale, the chief operating officer now directly owns 2,389 shares of the company's stock, valued at $323,828.95. This represents a 69.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Elisha W. Finney sold 600 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $138.92, for a total transaction of $83,352.00. Following the sale, the director now directly owns 3,252 shares in the company, valued at $451,767.84. This trade represents a 15.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,097 shares of company stock valued at $4,860,156. 1.50% of the stock is currently owned by insiders.

ICU Medical Stock Down 0.2%

NASDAQ:ICUI traded down $0.31 during trading hours on Friday, reaching $134.12. The company's stock had a trading volume of 279,898 shares, compared to its average volume of 278,492. The company has a market cap of $3.30 billion, a price-to-earnings ratio of -29.35 and a beta of 0.87. ICU Medical, Inc. has a one year low of $105.30 and a one year high of $196.26. The business's 50-day moving average is $137.87 and its 200-day moving average is $150.95. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The business had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. During the same quarter in the prior year, the business earned $0.96 earnings per share. The firm's revenue for the quarter was up 6.7% on a year-over-year basis. Equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on ICUI. Needham & Company LLC restated a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Wall Street Zen upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday, May 18th. Raymond James decreased their target price on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research note on Friday, May 9th. Finally, KeyCorp decreased their target price on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, ICU Medical currently has a consensus rating of "Buy" and an average target price of $192.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.